LLY · News · 20260911N
Acquisition - AtaiBeckley Deal
ELI LILLY & Co · 2026-09-11 · Importance 44 · Surprise 60 · In source text
Eli Lilly completed its acquisition of AtaiBeckley Inc. on September 11, 2026. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for treatment-resistant depression and other mental-health conditions. The transaction adds BPL-003, AtaiBeckley’s lead investigational program, to Lilly’s pipeline; the reported item did not disclose a purchase price or expected financial impact.
Key facts
- Eli Lilly and Company completed its acquisition of AtaiBeckley Inc., announced Sept. 11, 2026; AtaiBeckley is developing rapid-acting neuroplastogens including BPL-003, its lead investigational program for treatment-resistant depression. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | committed | — | Eli Lilly and Company completed its acquisition of AtaiBeckley Inc., announced Sept. 11, 2026; AtaiBeckley is developing rapid-acting… |